VITROS Troponin I ES Assay

• Performs competitively with currently available 5th-generation high-sensitivity Troponin assays

• Meets American College of Cardiology/European Society Cardiology guidelines for acceptable imprecision in a high-sensitivity assay (10% coefficient of variation at the 99th percentile)

• Enables accelerated rule-in/rule-out algorithms with validated clinical performance at the 99th percentile upper reference limit of normal

• Helps ensure that actionable results are reported with analyzer’s automated sample indices

• False positive Troponin T results have been reported in patients with kidney disease.¹ Troponin I biomarker elevations are more specific for myocardial damage than Troponin T elevations.²

   

1. Christenson RH et al. Comparison of 13 Commercially Available Cardiac Troponin Assays in a Multicenter North American Study. J Appl Lab Med. 2017; March; 544-561.

2. Twerenbold R. et al., Optimal Cutoff Levels of More Sensitive Cardiac Troponin Assays for the Early Diagnosis of Myocardial Infarction in Patients With Renal Dysfunction. Circulation. 2015;131:2041-2050

VITROS High-Sensitivity Troponin assay* 

• Features a high negative predictive value that helps reduce emergency department crowding and requires fewer tests to rule out

• Meets all International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) requirements for classification as a high-sensitivity troponin assay

• Shows excellent prognostic value as an aid in the assessment of cardiac-related mortality/MI and all-cause mortality over 30 days and 12 months

• Is compliant for use with guidelines for management of acute coronary syndrome, including ESC, AHA and NICE

   

*VITROS High-Sensitivity Troponin Assay is not available in all countries. Please check with your local QuidelOrtho representative for availability.

VITROS NT-proBNP II assay:

• Validated for use with ICON age-specific, cutoffs, which optimize diagnosis decisions, accounting for age and renal function with better specificity of acute dyspnea cases^1-5

• Long calibration interval at 70 days

• Automated, on-the-fly loading of consumables and reagents with no interruptions

• Intelligent sampling order to balance processing demands 

• Correlates well with most other NT-proBNP assays⁵

• Optimize patient outcomes and combine laboratory testing with emergency room testing: Our Quidel Triage True^® High Sensitivity Troponin I Test provides high diagnostic accuracy with results in less than 20 minutes*

   

1. Kim HN, Januzzi JL Jr. Natriuretic peptide testing in heart failure. Circulation. 2011;123(18):2015-2019. doi:10.1161/CIRCULATIONAHA.110.979500

2. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006; Aug;52(8):1528-1538. doi:10.1373/clinchem.2006.069575

3. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948-954. doi:10.1016/j.amjcard.2004.12.032

4. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J. 2006;27(3):330-337. doi:10.1093/eurheartj/ehi631

5. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663-670. doi:10.1016/j.jchf.2014.09.001